Literature DB >> 27705549

Mesothelioma from asbestos exposures: Epidemiologic patterns and impact in the United States.

Richard A Lemen1.   

Abstract

Mesothelioma, a rare tumor, is highly correlated with asbestos exposure. Mesothelioma, similar to all asbestos-related diseases, is dose/intensity dependent to some degree, and studies showed the risk of mesothelioma rises with cumulative exposures. Multiple processes occur in an individual before mesothelioma occurs. The impact of mesothelioma in the United States has been continuous over the last half century, claiming between 2,000 and 3,000 lives each year. Mesothelioma is a preventable tumor that is more frequently reported as associated with asbestos exposure among men than women. However, the rate of asbestos-associated mesothelioma is on the rise among women due to better investigation into their histories of asbestos exposure. It is of interest that investigators detected asbestos-associated cases of mesothelioma in women from nonoccupational sources-that is, bystander, incidental, or take-home exposures. It is postulated that asbestos-associated mesotheliomas, in both men and women, are likely underreported. However, with the implementation of the most recent ICD-10 coding system, the correlation of mesothelioma with asbestos exposure is expected to rise to approximately 80% in the United States. This study examined the demographic and etiological nature of asbestos-related mesothelioma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27705549     DOI: 10.1080/10937404.2016.1195323

Source DB:  PubMed          Journal:  J Toxicol Environ Health B Crit Rev        ISSN: 1093-7404            Impact factor:   6.393


  15 in total

Review 1.  Engineered nanomaterial-induced lysosomal membrane permeabilization and anti-cathepsin agents.

Authors:  Melisa Bunderson-Schelvan; Andrij Holian; Raymond F Hamilton
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2017       Impact factor: 6.393

Review 2.  Progress in the Management of Malignant Pleural Mesothelioma in 2017.

Authors:  Amanda J McCambridge; Andrea Napolitano; Aaron S Mansfield; Dean A Fennell; Yoshitaka Sekido; Anna K Nowak; Thanyanan Reungwetwattana; Weimin Mao; Harvey I Pass; Michele Carbone; Haining Yang; Tobias Peikert
Journal:  J Thorac Oncol       Date:  2018-03-08       Impact factor: 15.609

Review 3.  A Review of Pharmacologic Management in the Treatment of Mesothelioma.

Authors:  Eric P Borrelli; Conor G McGladrigan
Journal:  Curr Treat Options Oncol       Date:  2021-01-12

4.  Malignant Mesothelioma Mortality - United States, 1999-2015.

Authors:  Jacek M Mazurek; Girija Syamlal; John M Wood; Scott A Hendricks; Ainsley Weston
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-03-03       Impact factor: 17.586

Review 5.  Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy.

Authors:  Marco Tomasetti; Simona Gaetani; Federica Monaco; Jiri Neuzil; Lory Santarelli
Journal:  Front Oncol       Date:  2019-11-29       Impact factor: 6.244

6.  Malignant Pleural Mesothelioma Epidemiology in the United States From 2000 to 2016.

Authors:  Akesh Thomas; Sajin Karakattu; Jeanette Cagle; Girendra Hoskere
Journal:  Cureus       Date:  2021-04-21

Review 7.  Toward an Asbestos Ban in the United States.

Authors:  Richard A Lemen; Philip J Landrigan
Journal:  Int J Environ Res Public Health       Date:  2017-10-26       Impact factor: 3.390

8.  Effect of the BH3 Mimetic Polyphenol (-)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma.

Authors:  Monica Benvenuto; Rosanna Mattera; Joshua Ismaele Sticca; Piero Rossi; Chiara Cipriani; Maria Gabriella Giganti; Antonio Volpi; Andrea Modesti; Laura Masuelli; Roberto Bei
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

9.  Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation.

Authors:  Nishant S Kulkarni; Bhuvaneshwar Vaidya; Vineela Parvathaneni; Debarati Bhanja; Vivek Gupta
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923

10.  Ongoing downplaying of the carcinogenicity of chrysotile asbestos by vested interests.

Authors:  Xaver Baur; Arthur L Frank
Journal:  J Occup Med Toxicol       Date:  2021-02-23       Impact factor: 2.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.